DelveInsight’s, “IgE Receptor Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in IgE Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
IgE Receptor Antagonists: Overview
Immunoglobulin E is responsible for the pathogenesis of many allergic diseases including asthma. The primary role of IgE is defense against parasitic disease such as helminthes and protozoa. IgE, like all immunoglobulins, is composed of two light chains and two identical heavy chains. The heavy chain for IgE is epsilon. IgE is a monomer and consists of four constant regions. The constant region, C-epsilon-3, binds to both the low- and high-affinity IgE receptor. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness.
The companies and academics are working to assess challenges and seek opportunities that could influence IgE Receptor Antagonists R&D. The therapies under development are focused on novel approaches for IgE Receptor Antagonists.
This segment of the IgE Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IgE Receptor Antagonists Emerging Drugs
Genolair (Omalizumab biosimilar): Generium Pharmaceuticals
Omalizumab is a humanised monoclonal antibody produced using recombinant DNA that selectively binds to immunoglobulin (IgE). Omalizumab binds to IgE and blocks its interaction with a high affinity FcεRI receptor. Thus, there is a decrease in the amount of free IgE, which is a triggering factor for the cascade of allergic reactions. Omalizumab is the only class of biological anti-IgE therapy recommended for the treatment of atopic bronchial asthma; it helps withdraw or reduce the intake of glucocorticosteroids and also reduces the number and incidence of exacerbations.
Omalizumab (Xolair): Zhimeng Biopharma
Omalizumab is a monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria. Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids. Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated 6. In September 2018, a new prefilled syringe formulation of this drug was approved by the FDA. Currently, it is in Phase III stage of clinical trial evaluation to treat Peanut hypersensitivity.
Further product details are provided in the report……..
This segment of the report provides insights about the different IgE Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on IgE Receptor Antagonists
There are approx. 12+ key companies which are developing the IgE Receptor Antagonists. The companies which have their IgE Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Generium Pharmaceuticals.
DelveInsight’s report covers around 12+ products under different phases of clinical development like
IgE Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses IgE Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgE Receptor Antagonists drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
IgE Receptor Antagonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
IgE Receptor Antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Genolair: Generium Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
PG 102: Helixmith
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
UB 221: United BioPharma
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
HS-632: Hisun BioRay
Drug profiles in the detailed report…..
Inactive Products
IgE Receptor Antagonists Key Companies
IgE Receptor Antagonists Key Products
IgE Receptor Antagonists- Unmet Needs
IgE Receptor Antagonists- Market Drivers and Barriers
IgE Receptor Antagonists- Future Perspectives and Conclusion
IgE Receptor Antagonists Analyst Views
IgE Receptor Antagonists Key Companies
Appendix
List of Table
Table 1: Total Products for IgE Receptor Antagonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for IgE Receptor Antagonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Generium Pharmaceuticals
• Genentech
• Celltrion
• Glenmark Pharmaceuticals Ltd
• Helixmith
• United BioPharma
• Biosana
• PharmAbcine
• Hisun BioRay
• Aimmune Therapeutics
• Synermore Biologics
• Shanghai Biomabs Pharmaceuticals
• Eden Biologics
